Lupeol
Lup-20(29)-en-3-ol, (3beta)-, Fagarasterol, Clerodol, Monogynol B
- User: Female/Male
- Hormonal: Non-Hormonal
-
Delivery type:
- Not Yet Determined
-
Intended Duration:
- Not Yet Determined
- Development Stage: Discovery & Early Development
- Developer(s)/researcher(s): UC Berkeley, YourChoice Therapeutics
Details
- API: Lupeol
- Target: CatSper
-
Mechanism of Action:
- Not Yet Determined
- Inactive Materials: Not Yet Determined
- Regimen: Not Yet Determined
- MPT: Not Potential MPT
- Promising Attributes: To be established - concept is in early development
Product Status
Most recent evaluation suggests non-viability as contraceptive method.
History
Lupeol, a pentacyclic triterpenoid derived from Camellia japonica (among many other plants), has been considered as a possible API for male and female contraceptives due to its believed role in inhibiting activation of the CatSper Ca(2+)-channel. UC Berkeley media releases in 2019 confirmed that Drs. Lishko and Mannowetz are actively pursuing development. However, subsequent publications from the University of Copenhagen indicates that Lupeol cannot inhibit activation of the CatSper channel in human sperm. Development appears to have ceased.